Dr. Tara M. Graff
Dr. Graff earned her undergraduate degree in biology from Elmhurst College where she graduated in 2000. She then obtained her Masters degree from Loyola University in Chicago and earned her Doctor of Osteopathic Medicine credentials from Lake Erie College of Osteopathic Medicine in Bradenton, Florida in 2009.
She completed her residency training in Internal Medicine and a fellowship in Hematology and Oncology at the Medical College of Wisconsin at Froedtert Memorial Lutheran Hospital. She has led several clinical research projects and has published many original oncology and hematology articles.
Dr. Graff recently moved to the Des Moines area and joined Mission Cancer + Blood in August 2014.
Undergraduate Studies: Bachelor of Science in Biology with a Minor in Chemistry at Elmhurst College, Elmhurst, Illinois.
Masters Degree Studies: Masters of Science, Immunology Focus in Department of Cell Biology at Loyola University in Chicago, Maywood, Illinois.
Medical School: Lake Erie College of Osteopathic Medicine in Bradenton, Florida.
Residency (Internal Medicine): Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital in Milwaukee, Wisconsin.
Fellowship: Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital in Milwaukee, Wisconsin.
Certification: Internal Medicine; Medical Oncology
Oncology Research Activities: Dr. Graff serves on the National CAR-T Cell Advisory Board for Multiple Myeloma and on two separate National Lymphoma Advisory Boards. She is a member of the ECOG Clinical Trial Organization and is an educational speaker for Lymphoma and Breast Cancer.
Dr. Graff has served as the Primary Investigator for multiple clinical trials both past and present which includes:
- Sponsor: AstraZeneca Pharmaceuticals LP
- Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents. Open and enrolling.
- Sponsor: BMS
- PREAMBLE; ‘Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)’ Open and enrolling
- Sponsor: AbbVie
- M13-494 ‘A Phase 3 , Multicenter, Randomized , Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects with (t11;14) – Positive Relapsed or Refractory Multiple Myeloma’
- CDA and Contract to be signed by DORA
- M13-494 ‘A Phase 3 , Multicenter, Randomized , Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects with (t11;14) – Positive Relapsed or Refractory Multiple Myeloma’
- Sponsor: ICON
- ‘A Phase 2, Open Label, Randomized Study to Assess the Antitumor Activity and Safety of X in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + Gem) As First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma’
- Sponsor: ICON
- ‘A Randomized, Double-Blind, Parallel Group, Phase 3 trial to Compare the Efficacy, Safety and Immunogenicity of DRL-RI with Biosimilar in Subjects with Previously Untreated, Stage III-IV, DC20-Positive, Low tumor Burden Follicular Lymphoma’
- Sponsor: Lilly
- ‘Phase 3 Trial for Newly Diagnosed DLBCL, Involving the Addition of Enzastaurin + R-CHOP’
- CHI research arm CIRI has as ‘Just In Time’ model. Just In Time means Mercy – Des Moines/CIRI will have the trial open when we have identified a patient. I have been told it will take 5-10 days to open and enroll patient once a patient has been identified.
- ‘Phase 3 Trial for Newly Diagnosed DLBCL, Involving the Addition of Enzastaurin + R-CHOP’